Drug Information
| Drug General Information | Top | |||
|---|---|---|---|---|
| Drug ID |
DKJ93L
|
|||
| Drug Name |
131 I-omburtamab
|
|||
| Drug Type |
Antibody
|
|||
| Indication | Brain and central nervous system tumour [ICD-11: 2A00.11; ICD-10: C69-C72, C71] | Phase 2/3 | [1] | |
| Neuroblastoma [ICD-11: 2D11.2; ICD-9: 194] | Phase 2/3 | [1] | ||
| Company |
Y-mAbs Therapeutics
|
|||
| Target and Pathway | Top | |||
|---|---|---|---|---|
| Target(s) | B7 homolog 3 (CD276) | Target Info | Inhibitor | [2] |
| KEGG Pathway | Cell adhesion molecules (CAMs) | |||
| References | Top | |||
|---|---|---|---|---|
| REF 1 | ClinicalTrials.gov (NCT03275402) 131I-omburtamab Radioimmunotherapy for Neuroblastoma Central Nervous System/Leptomeningeal Metastases. U.S. National Institutes of Health. | |||
| REF 2 | IntraOmmaya compartmental radioimmunotherapy using 131 I-omburtamab-pharmacokinetic modeling to optimize therapeutic index. Eur J Nucl Med Mol Imaging. 2021 Apr;48(4):1166-1177. | |||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.